Sunday, October 12, 2025
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Analyst Maintains Neutral Rating on Cricut with Revised Price Target of 6

Elaine Mendonca by Elaine Mendonca
March 6, 2024
in Breaking News
0
Information Technology Stock Market Today
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

Jim Suva, an analyst at Citigroup, has decided to maintain a Neutral rating on Cricut (NASDAQ: CRCT) with a revised price target of $6, down from $8.5. This adjustment is in line with the overall sentiment among analysts, who have an average target price of $6.525 for Cricut, representing a spread of +32.62% from the previous closing price of $4.92 on March 6, 2024.

As of August 28, 2023, the average one-year price target for Cricut Inc was reported at $7.14, with forecasts ranging from $5.05 to $10.50. An earlier report from the same date indicated a current price target of $5.34, a consensus target of $9.50, and a range of $6.00 to $13.00.

CRCT Stock Shows Signs of Price Momentum on March 6, 2024

On March 6, 2024, CRCT stock showed signs of price momentum as it traded near the bottom of its 52-week range and below its 200-day simple moving average. Despite these indicators, the stock managed to make a slight gain on this particular day.

In pre-market trading on March 6, CRCT stock continued to show signs of improvement as it rose by $0.15. This increase indicated a more substantial gain compared to the previous day’s performance, suggesting that investors may have been more optimistic about the stock’s future prospects.

Overall, the performance of CRCT stock on March 6, 2024, demonstrated some positive price momentum despite trading near the bottom of its 52-week range and below its 200-day simple moving average. Investors will be keeping a close eye on how the stock performs in the coming days to see if this upward trend continues or if there are any potential challenges ahead.

CRCT Stock Analysis: Decline in Total Revenue and Net Income, but Potential Turnaround Ahead

On March 6, 2024, CRCT stock experienced mixed performances based on the financial data provided by CNN Money. The company’s total revenue for the past year was $886.30 million, which decreased by 32.15% compared to the previous year. However, the total revenue remained flat at $174.91 million for the last quarter.

Similarly, CRCT’s net income for the past year was $60.67 million, reflecting a decrease of 56.81% from the previous year. On a positive note, the net income increased by 7.5% since the last quarter, reaching $17.23 million.

Earnings per share (EPS) for CRCT stood at $0.28 for the past year, showing a decrease of 56.56% from the previous year. However, the EPS increased by 7.13% since the last quarter, reaching $0.08.

Overall, CRCT’s financial performance on March 6, 2024, indicates a decline in total revenue and net income compared to the previous year. However, there was a slight improvement in net income and EPS since the last quarter, suggesting a potential turnaround for the company in the upcoming quarters.

Tags: CRCT
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Finance_Budgeting (1)

B Riley Securities Analyst Reiterates Neutral Rating on LB Foster with Increased Price Target

Redefining Success: How Franchises Adapt to Economic Shifts and Market Demands

Analyst Reaffirms Sell Rating on Stellus Capital Investment with Lower Price Target

Biotechnology Stock Market Today (1)

Harvard Bioscience Inc Unveils CuttingEdge Product Advancements for Research at SOT Conference

Recommended

Axon Enterprise Stock

Axon Enterprise: AI-Powered Policing Solutions Fuel Record Growth

2 months ago
Walgreens Stock

Walgreens Completes Privatization in Landmark Acquisition Deal

3 weeks ago
NASDAQ 100 Stock

Tech-Led Rally Propels Nasdaq 100 Past Key Resistance

2 weeks ago
AbbVie Stock

AbbVie Secures Long-Term Revenue Stream Through Key Patent Settlement

4 weeks ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple Applovin BigBear.ai BioNTech Broadcom Coinbase Eli Lilly Fiserv IBM Intel Kraft Heinz Lockheed Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Nike NIO Nvidia Ocugen Opendoor Oracle Oxford Lane Capital Palantir PayPal Plug Power Realty Income Robinhood Rocket Lab USA Salesforce Strategy Super Micro Computer Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics Wolfspeed
No Result
View All Result

Highlights

Wall Street Analysts Rally Behind Water Technology Leader Xylem

Wall Street Bullish on Micron as Major Banks Raise Price Targets

Akari Therapeutics Shares Swing on Dual Patent Filings

Sea Limited: A Tech Titan’s Three-Pronged Path to Profitability

Apple’s Leadership Transition and Earnings Outlook in Focus

Enovix Shares Approach Critical Milestone

Trending

Fannie Mae Stock
Analysis

Fannie Mae Shares Face Critical Test After Stellar Rally

by Robert Sasse
October 12, 2025
0

The extraordinary momentum behind Fannie Mae's equity appears to be moderating following a breathtaking 907 percent surge...

Hercules Capital Stock

Hercules Capital Shares: A Battle Between Strong Fundamentals and Market Pessimism

October 12, 2025
SunPower Stock

SunPower Shares Continue Downward Spiral as Retention Costs Raise Concerns

October 12, 2025
Xylem Stock

Wall Street Analysts Rally Behind Water Technology Leader Xylem

October 12, 2025
Micron Stock

Wall Street Bullish on Micron as Major Banks Raise Price Targets

October 12, 2025

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Fannie Mae Shares Face Critical Test After Stellar Rally
  • Hercules Capital Shares: A Battle Between Strong Fundamentals and Market Pessimism
  • SunPower Shares Continue Downward Spiral as Retention Costs Raise Concerns

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com